EHang Holdings Ltd - ADR vs Novavax Inc — how do they compare? EHang Holdings Ltd - ADR trades at $5.79 (market cap $437.63M), while Novavax Inc trades at $7.96 (market cap $1.31B). The key difference: Novavax Inc is far larger — about 3× EHang Holdings Ltd - ADR's market cap, and Novavax Inc is trading nearer its 52-week high, EHang Holdings Ltd - ADR nearer its low. Which is the better fit depends on your goals.
| EH | NVAX | |
|---|---|---|
Market Cap | $437.63M | $1.31B |
Sector | Industrials | Health |
52-Week High | $19.44 | $11.19 |
52-Week Low | $4.90 | $6.22 |
Enterprise Value | $376.84M | $889.30M |
Signals from Pluang's Aura AI — not financial advice
EHang Holdings (EH) trades at $5.70, up 0.18% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages. The company reported Q1 2026 revenue of $418 million, with a net loss of $276 million, reflecting ongoing profitability challenges despite a high gross margin of 61.53%. Recent news includes the successful pilotless eVTOL flight in Kazakhstan, highlighting operational progress amid a volatile year for air taxi stocks.
The outlook remains speculative, with significant growth potential in the advanced air mobility market offset by persistent losses and competitive pressures. Risks include execution hurdles and funding needs, while analyst sentiment is divided with a consensus price target of $6.97 suggesting modest upside from current levels.
NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.
The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.
Trailing returns across standard periods
Latest headlines on both assets
EHang Holdings Ltd is an autonomous aerial vehicle (AAV) technology platform company. It focuses on making safe, autonomous and eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with AAV products and commercial solutions: air mobility (including passenger transportation and logistics), smart city management and aerial media solutions. As the forerunner of cutting-edge AAV technologies and commercial solutions in the global Urban Air Mobility industry, it continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.
Read more on EH →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →